OBJECTIVE: Glutamate and glutamine were examined in vivo in nonpsychotic adolescents at high genetic risk for schizophrenia by using 3-T proton magnetic resonance spectroscopy ((1)H-MRS). METHOD: Spectra from the right medial frontal lobe of 20 adolescents who had a parent with schizophrenia (high-risk group; mean age=16.4 years) were compared with spectra obtained from adolescent offspring of parents with no history of schizophrenia (low-risk group; mean age=16.7 years). RESULTS: Glutamate/glutamine was significantly higher in the adolescents at high genetic risk for schizophrenia than in the low-risk offspring. Age, premorbid adjustment scale scores, and other (1)H-MRS metabolites did not differ between groups. Global Assessment of Functioning Scale scores and socioeconomic status were lower in the high-risk group. DISCUSSION: The finding of glutamate/glutamine abnormalities in a group of subjects at high genetic risk for schizophrenia lends support for both the glutamate dysfunction and neurodevelopmental hypotheses for schizophrenia.
OBJECTIVE:Glutamate and glutamine were examined in vivo in nonpsychotic adolescents at high genetic risk for schizophrenia by using 3-T proton magnetic resonance spectroscopy ((1)H-MRS). METHOD: Spectra from the right medial frontal lobe of 20 adolescents who had a parent with schizophrenia (high-risk group; mean age=16.4 years) were compared with spectra obtained from adolescent offspring of parents with no history of schizophrenia (low-risk group; mean age=16.7 years). RESULTS:Glutamate/glutamine was significantly higher in the adolescents at high genetic risk for schizophrenia than in the low-risk offspring. Age, premorbid adjustment scale scores, and other (1)H-MRS metabolites did not differ between groups. Global Assessment of Functioning Scale scores and socioeconomic status were lower in the high-risk group. DISCUSSION: The finding of glutamate/glutamine abnormalities in a group of subjects at high genetic risk for schizophrenia lends support for both the glutamate dysfunction and neurodevelopmental hypotheses for schizophrenia.
Authors: Olga Rass; Jennifer K Forsyth; Giri P Krishnan; William P Hetrick; Mallory J Klaunig; Alan Breier; Brian F O'Donnell; Colleen A Brenner Journal: Schizophr Res Date: 2012-01-28 Impact factor: 4.939
Authors: Juan R Bustillo; Hongji Chen; Charles Gasparovic; Paul Mullins; Arvind Caprihan; Clifford Qualls; William Apfeldorf; John Lauriello; Stefan Posse Journal: Biol Psychiatry Date: 2010-10-20 Impact factor: 13.382
Authors: Ragy R Girgis; Seth Baker; Xiangling Mao; Roberto Gil; Daniel C Javitt; Joshua T Kantrowitz; Meng Gu; Daniel M Spielman; Najate Ojeil; Xiaoyan Xu; Anissa Abi-Dargham; Dikoma C Shungu; Lawrence S Kegeles Journal: Psychiatry Res Date: 2019-03-12 Impact factor: 3.222
Authors: Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis Journal: Schizophr Res Date: 2014-01-11 Impact factor: 4.939
Authors: Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti Journal: Biol Psychiatry Date: 2010-06-08 Impact factor: 13.382
Authors: Min Soo Byun; Jung-Seok Choi; So Young Yoo; Do-Hyung Kang; Chi-Hoon Choi; Dong Pyo Jang; Wi Hoon Jung; Myung Hun Jung; Joon Hwan Jang; Jong-Min Lee; Jun Soo Kwon Journal: Psychiatry Investig Date: 2009-11-21 Impact factor: 2.505
Authors: Meredith A Reid; Nina V Kraguljac; Kathy B Avsar; David M White; Jan A den Hollander; Adrienne C Lahti Journal: Schizophr Res Date: 2013-05-21 Impact factor: 4.939